Analytical Data
-
Gene name
IPO11
- Application
-
Alternative Names
RanBP11; SLRN; Ran-binding protein 11
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UI26
-
Expression Region
Met1~Gly237
-
Molecular Weight
31kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The IPO11 protein, a member of the importin family, plays a critical role in the nucleocytoplasmic transport of proteins, especially those containing a nuclear localization signal. Research into IPO11 has gained traction due to its involvement in various biological processes, including cell cycle regulation and gene expression. Abnormalities in nucleocytoplasmic transport are linked to several diseases, including cancer and neurodegenerative disorders, making IPO11 a potential target for therapeutic interventions. Studies have shown that IPO11 is not only crucial for the import of nuclear proteins but also may have a role in the export of certain factors from the nucleus. Its function and regulatory mechanisms remain an area of intense investigation, particularly in understanding the molecular basis of disease. The development of recombinant IPO11 protein has been essential for these studies, allowing researchers to explore its structural and functional properties in detail. By using techniques such as X-ray crystallography and advanced biochemical assays, scientists aim to elucidate the interactions of IPO11 with its cargo and other cellular components. This understanding could lead to the identification of new biomarkers and treatment strategies for diseases associated with impaired nucleocytoplasmic transport. As a result, IPO11 is positioned at the intersection of fundamental research and applied biomedical science, highlighting its significance in both cellular function and the development of novel therapeutic approaches.
